Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
复制标题
DOI：
10.1186/s13195-023-01203-y
复制
发表时间：
2023-03-16
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
代谢综合征和胰岛素抵抗的生物标志物、血浆甘油三酯/高密度脂蛋白胆固醇（TG/HDL- c）比率与轻度认知障碍（MCI）和阿尔茨海默病（AD）痴呆阶段认知能力下降率之间的关系尚不清楚。外周和脑脊液（CSF）载脂蛋白A1 （ApoA1）水平在认知能力下降中的作用也是不清楚的，载脂蛋白A1是HDL的一个关键功能成分。在这里，我们评估了基线血浆TG/HDL-C比值、CSF和血浆ApoA1水平及其与MCI和AD痴呆期认知能力下降的关系。一项来自阿尔茨海默病神经影像学倡议的回顾性纵向研究（156名参与者，106名轻度认知障碍患者，50名老年痴呆症患者），平均随访时间为4.0年（SD 2.8）。评估基线血浆TG/HDL-C、血浆和CSF ApoA1及其与炎症和血脑屏障（BBB）生物标志物和纵向认知结局的关系。在控制已知协变量后，采用多变量线性混合效应模型评估基线分析对迷你精神状态检查（MMSE）、临床痴呆评分-盒和（CDR-SB）和逻辑记忆延迟回忆（LM）评分的纵向变化的影响。共有156名参与者，其中女性98人，占63%；平均年龄74.9岁（SD 7.3）。在基线时，MCI组和痴呆组在TG/HDL-C （Wilcoxon W统计值= 0.39,p = 0.39）和CSF ApoA1水平上无显著差异（W = 3642, p = 0.29），但痴呆组血浆ApoA1高于MCI组（W = 4615, p = 0.01）。在MCI组和痴呆组中，TG/HDL-C比值越高，CDR-SB下降越快。较高的血浆ApoA1水平与MCI患者MMSE和LM的更快下降有关，而相比之下，较高的CSF ApoA1水平与MCI患者MMSE认知能力下降较慢有关。脑脊液和血浆ApoA1也与血脑屏障完整性的生物标志物显示相反的相关性。脑脊液而非血浆ApoA1水平与糖尿病并发症中AGE-RAGE信号通路中的炎症分析呈正相关（KEGG ID:KO04933）。代谢综合征的生物标志物与MCI和痴呆个体的认知能力下降率有关。血浆TG/HDL-C比值和血浆ApoA1升高与MCI和痴呆患者的认知预后恶化有关。CSF ApoA1和血浆ApoA1可能在MCI期AD的进展中有不同的作用。在线版本包含补充材料，可在10.1186/s13195-023-01203-y获得。
The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and dementia stages of Alzheimer’s disease (AD) is unknown. The role of peripheral and cerebrospinal fluid (CSF) levels of Apolipoprotein A1 (ApoA1), a key functional component of HDL, on cognitive decline also remains unclear among them. Here we evaluate baseline plasma TG/HDL-C ratio and CSF and plasma ApoA1 levels and their relation with cognitive decline in the MCI and Dementia stages of AD. A retrospective longitudinal study (156 participants; 106 MCI, 50 AD dementia) from the Alzheimer’s Disease Neuroimaging Initiative, with an average of 4.0 (SD 2.8) years follow-up. Baseline plasma TG/HDL-C, plasma, and CSF ApoA1 and their relationship to inflammation and blood–brain barrier (BBB) biomarkers and longitudinal cognitive outcomes were evaluated. Multivariable linear mixed effect models were used to assess the effect of baseline analytes with longitudinal changes in Mini-Mental State Exam (MMSE), Clinical Dementia Rating–Sum of Boxes (CDR-SB), and Logical Memory delayed recall (LM) score after controlling for well-known covariates. A total of 156 participants included 98 women, 63%; mean age was 74.9 (SD 7.3) years. At baseline, MCI and dementia groups did not differ significantly in TG/HDL-C (Wilcoxon W statistic = 0.39, p = 0.39) and CSF ApoA1 levels (W = 3642, p = 0.29), but the dementia group had higher plasma ApoA1 than the MCI group (W = 4615, p = 0.01). Higher TG/HDL-C ratio was associated with faster decline in CDR-SB among MCI and dementia groups. Higher plasma ApoA1 was associated with faster decline in MMSE and LM among MCI, while in contrast higher CSF ApoA1 levels related to slower cognitive decline in MMSE among MCI. CSF and plasma ApoA1 also show opposite directional correlations with biomarkers of BBB integrity. CSF but not plasma levels of ApoA1 positively correlated to inflammation analytes in the AGE-RAGE signaling pathway in diabetic complications (KEGG ID:KO04933). Biomarkers of metabolic syndrome relate to rate of cognitive decline among MCI and dementia individuals. Elevated plasma TG/HDL-C ratio and plasma ApoA1 are associated with worse cognitive outcomes in MCI and dementia participants. CSF ApoA1 and plasma ApoA1 likely have different roles in AD progression in MCI stage. The online version contains supplementary material available at 10.1186/s13195-023-01203-y.
登录
查看更多内容
DOI：
10.1590/s1807-59322008000400003
发表时间：
2008-08
期刊：
Clinics (Sao Paulo, Brazil)
影响因子：
--
作者：
da Luz PL;Favarato D;Faria-Neto JR Jr;Lemos P;Chagas AC
通讯作者：
Chagas AC
影响因子：
7.2
作者：
Choi, Hyo Jung;Byun, Min Soo;Lee, Dong Young
通讯作者：
Lee, Dong Young
DOI：
10.3233/jad-121138
发表时间：
2013
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Katsumata Y;Todoriki H;Higashiuesato Y;Yasura S;Ohya Y;Willcox DC;Dodge HH
通讯作者：
Dodge HH
影响因子：
4.2
作者：
Merched, A;Xia, Y;Siest, G
通讯作者：
Siest, G
影响因子：
9.3
作者：
Li, Chaoyang;Ford, Earl S.;Reaven, Gerald M.
通讯作者：
Reaven, Gerald M.